HRP20260351T1 - C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane - Google Patents

C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane

Info

Publication number
HRP20260351T1
HRP20260351T1 HRP20260351TT HRP20260351T HRP20260351T1 HR P20260351 T1 HRP20260351 T1 HR P20260351T1 HR P20260351T T HRP20260351T T HR P20260351TT HR P20260351 T HRP20260351 T HR P20260351T HR P20260351 T1 HRP20260351 T1 HR P20260351T1
Authority
HR
Croatia
Prior art keywords
c5ar1
taxane
inhibitors
treatment
hypersensitivity reactions
Prior art date
Application number
HRP20260351TT
Other languages
English (en)
Croatian (hr)
Inventor
Marcello Allegretti
Andrea Aramini
Piergiorgio AMENDOLA
Laura Brandolini
Maria Candida Cesta
Anna SIRICO
Original Assignee
Dompé Farmaceutici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompé Farmaceutici Spa filed Critical Dompé Farmaceutici Spa
Publication of HRP20260351T1 publication Critical patent/HRP20260351T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20260351TT 2021-03-17 2022-03-17 C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane HRP20260351T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
EP22716203.9A EP4308114B1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
HRP20260351T1 true HRP20260351T1 (hr) 2026-04-24

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20260351TT HRP20260351T1 (hr) 2021-03-17 2022-03-17 C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane

Country Status (15)

Country Link
US (1) US20240180888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308114B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512472A (cg-RX-API-DMAC7.html)
BR (1) BR112023018826A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212816A1 (cg-RX-API-DMAC7.html)
DK (1) DK4308114T3 (cg-RX-API-DMAC7.html)
FI (1) FI4308114T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260351T1 (cg-RX-API-DMAC7.html)
IL (1) IL305727A (cg-RX-API-DMAC7.html)
LT (1) LT4308114T (cg-RX-API-DMAC7.html)
PL (1) PL4308114T3 (cg-RX-API-DMAC7.html)
RS (1) RS67911B1 (cg-RX-API-DMAC7.html)
SI (1) SI4308114T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600118T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022195017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543631A (zh) * 2024-03-14 2025-11-16 美商凡況生化公司 嗒嗪酮c5ar1拮抗劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
DE69828615T2 (de) * 1997-10-31 2005-12-01 Walter Reed Army Institute Of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
RU2002113659A (ru) * 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
JP5374157B2 (ja) * 2005-11-24 2013-12-25 ドムペ・ファ.ル.マ・ソチエタ・ペル・アツィオーニ (r)−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
PL4308114T3 (pl) 2026-05-04
EP4308114B1 (en) 2026-02-11
RS67911B1 (sr) 2026-04-30
EP4308114A1 (en) 2024-01-24
WO2022195017A1 (en) 2022-09-22
FI4308114T3 (fi) 2026-03-25
DK4308114T3 (da) 2026-03-23
IL305727A (en) 2023-11-01
JP2024512472A (ja) 2024-03-19
LT4308114T (lt) 2026-03-25
CA3212816A1 (en) 2022-09-22
BR112023018826A2 (pt) 2024-03-12
SI4308114T1 (sl) 2026-05-29
SMT202600118T1 (it) 2026-05-12

Similar Documents

Publication Publication Date Title
EP4041212C0 (en) MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
EP3595672C0 (en) COMPOUNDS FOR USE IN METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS
EP4352042A4 (en) COMPOUNDS FOR THE TREATMENT OF SARS
HUE049591T2 (hu) Makrociklusos MCL-1 inhibitorok rák kezelésére
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
PL3455258T3 (pl) Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1
IL256056A (en) Ezh2 inhibitors for treating lymphoma
SI3426250T1 (sl) Zdravljenje pacienta s substratnim zdravilom CYP3A4 s kontraindikacijo za sočasno dajanje z močnim zaviralcem CYP3A4
SI3773593T1 (sl) Zdravljenje hidradenitisa suppurative z zaviralci jak
IL287904A (en) Combination treatment of arthritic disease
IL261015B (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
EP3589289A4 (en) INHIBITION OF SMARCA2 FOR THE TREATMENT OF CANCER
EP3464643A4 (en) USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
IL283659A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
SI3833665T1 (sl) Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
IL282041A (en) Egfr inhibitors for treating keratodermas
EP3852877A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINITIS PIGMENTOSA
SI3886799T1 (sl) Sestavki za zdravljenje izpadanja las
EP4426682A4 (en) SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
IL291424A (en) Use of dkk-1 inhibitors for treating cancer